|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Expenses | |||||
| Research and development | |||||
| Consulting, wages and benefits | |||||
| Directors' fees | |||||
| Investor relations | |||||
| Professional fees | |||||
| General and administrative | |||||
| Public company costs | |||||
| Travel | |||||
| Amortization of property and equipment | |||||
| Amortization of intangible assets | |||||
| Impairment of intangible assets | |||||
| Share-based payments | |||||
| Loss before other items | |||||
| Fair value adjustment on derivative warrant liability | |||||
| Foreign exchange loss | |||||
| Interest income | |||||
| Transaction costs on derivative warrant liability | |||||
| Net loss for the year | |||||
| Other comprehensive loss: | |||||
| Items that may be subsequently reclassified to profit or loss: | |||||
| Total loss and comprehensive loss for the year | |||||
| Basic and diluted loss per common share | |||||
| Basic loss per common share | |||||
| Diluted loss per common share | |||||
| Weighted average number of common shares outstanding | |||||
| Weighted average number of common shares outstanding, Basic | |||||
| Weighted average number of common shares outstanding, Diluted | |||||
Loading...